Header cover image

Hong Kong (HSI) Pharma Industry Analysis

UpdatedMay 22, 2025
DataAggregated Company Financials
Companies39
  • 7D8.8%
  • 3M24.1%
  • 1Y20.4%
  • YTD31.0%

The Pharma industry is up 8.8% in the last week, with Hansoh Pharmaceutical Group up 14%. This takes the industry's 12 month performance to a gain of 20%. As for the next few years, earnings are expected to grow by 11% per annum.

Industry Valuation and Performance

Has the Hong Kong Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 22 May 2025HK$547.6bHK$476.3bHK$29.1b10.9x18.8x1.1x
Sat, 19 Apr 2025HK$473.0bHK$466.5bHK$28.6b10.2x16.5x1x
Mon, 17 Mar 2025HK$464.1bHK$465.2bHK$32.0b9.1x14.5x1x
Wed, 12 Feb 2025HK$420.7bHK$461.1bHK$31.8b8.6x13.2x0.9x
Fri, 10 Jan 2025HK$409.5bHK$458.9bHK$31.7b8.3x12.9x0.9x
Sun, 08 Dec 2024HK$443.5bHK$462.5bHK$31.9b8.3x13.9x1x
Tue, 05 Nov 2024HK$447.2bHK$473.0bHK$32.8b8.2x13.6x0.9x
Thu, 03 Oct 2024HK$498.2bHK$477.7bHK$33.1b7.9x15x1x
Sat, 31 Aug 2024HK$444.1bHK$475.6bHK$33.3b7.8x13.3x0.9x
Mon, 29 Jul 2024HK$422.3bHK$458.9bHK$32.6b7.5x13x0.9x
Wed, 26 Jun 2024HK$446.0bHK$462.1bHK$33.8b7.8x13.2x1x
Fri, 24 May 2024HK$466.7bHK$462.9bHK$33.7b8.5x13.8x1x
Sun, 21 Apr 2024HK$423.1bHK$464.6bHK$33.8b7.5x12.5x0.9x
Tue, 19 Mar 2024HK$468.8bHK$470.2bHK$33.3b7.8x14.1x1x
Thu, 15 Feb 2024HK$413.8bHK$471.1bHK$33.6b6.6x12.3x0.9x
Sat, 13 Jan 2024HK$456.0bHK$472.1bHK$33.7b7.6x13.5x1x
Mon, 11 Dec 2023HK$471.9bHK$471.9bHK$33.7b7.4x14x1x
Wed, 08 Nov 2023HK$495.7bHK$469.5bHK$31.9b7x15.5x1.1x
Fri, 06 Oct 2023HK$436.3bHK$469.5bHK$31.6b6.6x13.8x0.9x
Sun, 03 Sep 2023HK$428.9bHK$470.9bHK$31.5b6.9x13.6x0.9x
Tue, 01 Aug 2023HK$489.4bHK$446.9bHK$27.9b9.2x17.5x1.1x
Thu, 29 Jun 2023HK$500.1bHK$445.5bHK$27.5b9.6x18.2x1.1x
Sat, 27 May 2023HK$519.2bHK$449.4bHK$28.0b8.6x18.5x1.2x
Mon, 24 Apr 2023HK$566.8bHK$454.3bHK$28.8b9.1x19.6x1.2x
Wed, 22 Mar 2023HK$550.9bHK$443.0bHK$35.1b10.5x15.7x1.2x
Fri, 17 Feb 2023HK$602.5bHK$445.8bHK$35.4b10.9x17x1.4x
Sun, 15 Jan 2023HK$649.2bHK$448.8bHK$35.8b11.5x18.1x1.4x
Tue, 13 Dec 2022HK$618.8bHK$441.3bHK$34.6b10.8x17.9x1.4x
Thu, 10 Nov 2022HK$571.7bHK$435.3bHK$33.7b8.8x17x1.3x
Sat, 08 Oct 2022HK$527.2bHK$516.1bHK$39.3b7.9x13.4x1x
Mon, 05 Sep 2022HK$554.9bHK$521.7bHK$41.3b9x13.4x1.1x
Wed, 03 Aug 2022HK$568.0bHK$512.2bHK$51.8b7.5x11x1.1x
Fri, 01 Jul 2022HK$639.3bHK$514.5bHK$51.9b10x12.3x1.2x
Sun, 29 May 2022HK$580.9bHK$514.5bHK$51.9b8.7x11.2x1.1x
Price to Earnings Ratio

11.2x


Total Market Cap: HK$580.9bTotal Earnings: HK$51.9bTotal Revenue: HK$514.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Pharma Industry Price to Earnings3Y Average 14.8x202320242025
Current Industry PE
  • Investors are optimistic on the Hong Kong Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 18.8x which is higher than its 3-year average PE of 14.8x.
  • The industry is trading close to its 3-year average PS ratio of 1.1x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 18% per year over the last three years,
  • Revenues have also declined 2.5% per year.
  • This means overall sales from these companies are declining and profits are subsequently falling as well.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare industry?

HK Market1.56%
Healthcare7.71%
Pharma8.84%
Pharma8.84%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
3692 Hansoh Pharmaceutical GroupHK$25.7013.7%
+HK$18.4b
48.7%PE32.2x
1093 CSPC Pharmaceutical GroupHK$6.4813.5%
+HK$8.8b
0.6%PE15.8x
1177 Sino BiopharmaceuticalHK$4.217.9%
+HK$5.5b
43.7%PE36.1x
2096 Simcere Pharmaceutical GroupHK$10.3423.1%
+HK$4.8b
76.8%PE32.1x
460 Sihuan Pharmaceutical Holdings GroupHK$0.9137.9%
+HK$2.3b
56.9%PS4x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

512

HK$8.69

Grand Pharmaceutical Group

7D

6.1%

1Y

80.7%

3737

HK$0.90

Zhongzhi Pharmaceutical Holdings

7D

-4.3%

1Y

-18.9%

1889

HK$0.33

Sanai Health Industry Group

7D

-2.9%

1Y

-51.1%

455

HK$0.14

Tianda Pharmaceuticals

7D

-2.1%

1Y

-42.1%

1477

HK$7.70

Ocumension Therapeutics

7D

45.8%

1Y

13.6%

867

HK$9.07

China Medical System Holdings

7D

10.9%

1Y

34.0%

8329

HK$0.16

Shenzhen Neptunus Interlong Bio-technique

7D

-8.9%

1Y

1.2%